^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Biochem Biophys Res Commun
    Title:

    Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma

    Published date:
    10/20/2020
    Excerpt:
    In conclusion, we identified vandetanib as a novel therapeutic option for cutaneous SCC, especially in tumors with high EGFR expression.
    DOI:
    10.1016/j.bbrc.2020.07.111